 |
|
|
|
|
|
Back to the HDR
2006 programme >> |
|
|
|
|
|
 |
|
Session 1: Protein Kinases as Drug targets
Chair: Prof. Raimo K. Tuominen, University of Helsinki
Lectures and Oral Communications in Red are
from members of our Consortium. |
|
|
|
ATP-Binding Site of Protein Kinases
Dr. Doriano Fabbro,
Novartis, Switzerland
|
|
|
|
The Visualization of Anchored Kinase Signaling Events
Dr. John D. Scott,
Oregon Health and Science
University, USA
|
|
|
|
Regulatory Domains of PKC as Drug Targets
Dr. Victor Marquez,
NCI, NIH, USA
|
|
|
|
A Staurosporine Story: Indolocarbazole Orthoamides and Fluorinated Analogs of
LY333531
Prof. Peter Goekjian,
CNRS Lyon, France
|
ATP-Binding Site of Protein Kinases
Dr. Doriano Fabbro,
Novartis, Switzerland
|
|
Protein kinases play an essential role in many
signaling pathways and have the potential to contribute to diseases ranging from
cancer and inflammation to diabetes, cardiovascular as well as other disorders.
Therefore protein kinases have become one of the most populated class of
druggable targets. Identification of kinase specificity and functional
validation of kinase as targets has been a challenge, but innovative approaches
have been developed to address these issues and over the years a few lessons
have been learned:
1. Kinase inhibitors can bind to the kinase by at least four different bind
modes: |
|
|
|
|
(i) direct competition with ATP in the ATP binding site;
(ii) engagement of an adjacent allosteric binding site in the ATP pocket
usually accessible when the activation loop is in the inactive conformation;
and
(iii) binding at sites remote from the ATP site (but still close to the ATP)
that impact kinase activity;
(iv) binding outside of the ATP binding pocket (truly allosteric).
|
 |
|
Dr. Doriano Fabbro |
|
2. Kinases can escape inhibition by mutating
key residues in their catalytic domain and thus become resistant to the
kinase inhibitors.
3. Kinase that have gain of function mutations may be more sensitive or
resistant to inhibition by kinase inhibitors than the wt form of the kinase.
In this lecture case studies of drug development will be discussed which
will provide insights on strategies that are being employed to generate
second generation kinase inhibitors including structure-based design,
screening approaches, compound selectivity between kinases and the
development of the non-ATP competitive kinase inhibitors.
|
|
[ Top ] |
The Visualization of Anchored Kinase Signaling Events
John D. Scott
Oregon Health and Science University, USA |
|
Multiprotein signaling networks create focal points of enzyme activity that
disseminate the intracellular action of many hormones and neurotransmitters.
Accordingly, the spatio-temporal activation of protein kinases and phosphatases is an important factor in controlling where and when
phosphorylation events occur. Anchoring proteins provide a molecular
framework that orients these enzymes towards selected substrates. A-kinase
anchoring proteins (AKAPs) are signal-organizing molecules that
compartmentalize the cAMP dependent protein kinase, phosphodiesterases and a
variety of enzymes that are regulated by second messengers. Using a
combination of live cell imaging, biochemical, genetic and
electrophysiological techniques I will discuss two emerging principles in
AKAP signaling: the combinatorial assembly of different enzymes on the same
AKAP backbone; and the dynamic reorganization of AKAP complexes. |

John D. Scott |
|
[ Top ]
|
Regulatory
Domains of PKC as Drug Targets
Dr. Victor Marquez,
NCI, NIH, USA |
 |
The weak binding affinity of DAG for the C1 domains of PKC’s and the
complicated structures and restricted supply of natural product ligands
prompted us to devise a strategy to enhance the affinity of DAG by means of
an optimized DAG-lactone template. DAG-lactones have been designed to
selectively direct the flow of information from the DAG signaling pathways
through its multiple signal transducers that contain DAG-responsive C1
domains.
|
|
Dr. Victor Marquez |
Because the substrates for PKC phosphorylation and their roles in downstream
events are poorly understood, our efforts have been directed to the head of
these pathways, at the level of DAG-C1 domain interactions. Since the actual
DAG binding site represents a complex of lipid bilayer and C1 domain, for
which the C1 domain represents only a half-site, the interactions with the
phospholipid head groups are important albeit difficult to predict. We
surmised that the specific cellular localization and response of an
activated isozyme ought to be determined in part by the different lipid
composition of the membranes, and the targeting information intrinsic to the
individual isoform. Because structure-activity analyses incorporating the
lipid bilayer are still rudimentary, we have decided to explore this aspect
indirectly. Thus, we have implemented the syntheses of combinatorial
libraries where randomly chosen groups decorating the DAG-lactones generate
a series of chemical “zip codes” that create a different PKC-lipid
microenvironment capable of directing the activated complex to different
sub-cellular sites. Our preliminary results provide a strong
proof-of-principle for the concept of chemical “zip codes” which form the
basis for new therapeutic strategies selectively targeting these pathways. |
|
|
|
[ Top ] |
A Staurosporine
Story: Indolocarbazole Orthoamides and Fluorinated Analogs of
LY333531
Prof. Peter Goekjian,
CNRS Lyon, France
Anne Jochum1, Thierry Lamouille1, Stein Dřskeland2, Peter Parker & Peter
Goekjian1,3
1 Universite Claude Bernard-Lyon 1, UMR 5181, Villeurbanne, France
2 University of Bergen, Bergen, Norway
3 CR-UK London Research Institute, London, UK
|
|
 |
Staurosporine, initially identified as a protein kinase C inhibitor, has
turned out to be a highly promiscuous inhibitor. It has inspired a
remarkable array of novel compounds, and many highly selective compounds
have been found based on this lead structure. We will describe a few aspects
of our own foray in this area, in particular with respect to fluoro analogs
of LY333531 (ruboxistaurin) and orthoamide analogs of rebeccamycin.
|
|
Prof. Peter Goekjian |
Previous results in our laboratories suggested that two conformations
dominate in the 14-membered ring macrocyclic bis(indolyl)maleimides. We
believe that placing a fluorine atom at the 4-position of one of the indole
rings of LY333531 would create an unfavorable lone-pair/lone pair
interaction with the carbonyl, and favor a conformation in which the
4-fluorindole ring is perpendicular to the maleimide ring. Indole-fluorinated
macrocyclic bisindolylmaleimide have been synthesized to test the hypothesis
that this conformation is responsible for the selectivity of LY333531 for
the beta isoform of PKC.
Synthetic studies towards staurosporine led us to a new methodology that
allowed us to prepare an orthothioamide of bis(indolyl)maleimide. This key
intermediate was converted to a family of orthoamide analogs of rebeccamycin.
These compounds may allow us to explore the steric, electronic, and
conformational space around the key glycosidic bond of the indolocarbazole
alkaloids. |
|
[ Top ] |
Back to the
HDR 2006 programme >> |
[ Contact us ]
Updated 12th July 2006
webmaster (at) proteinkinase-research.org
|